VERO Biotech’s Post

Have you started transforming your Key Account Management (KAM) program to stay competitive in a new digital era? Many pharma, biotech and medtech companies have started the journey but have found themselves confronted with a series of pain points. Find out how you can grasp KAM’s full potential.

It's early in 2024 and we're already witnessing some major changes in the BioPharma Industry. Our own CEO, Cory Lewis, provides his three key trends that will shape the CDMO industry in 2024. See article here: https://lnkd.in/gaWJXTc4 What other changes or trends do you see coming?

Thoughts on this? >> Weeks after closing Bristol Myers deal, Karuna's ex-CEO heads to Blackstone-backed Anthos >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #healthcare #pharma #biotech

𝗪𝗲𝗲𝗸𝘀 𝗮𝗳𝘁𝗲𝗿 𝗰𝗹𝗼𝘀𝗶𝗻𝗴 𝗕𝗿𝗶𝘀𝘁𝗼𝗹 𝗠𝘆𝗲𝗿𝘀 𝗱𝗲𝗮𝗹, 𝗞𝗮𝗿𝘂𝗻𝗮'𝘀 𝗲𝘅-𝗖𝗘𝗢 𝗵𝗲𝗮𝗱𝘀 𝘁𝗼 𝗕𝗹𝗮𝗰𝗸𝘀𝘁𝗼𝗻𝗲-𝗯𝗮𝗰𝗸𝗲𝗱 𝗔𝗻𝘁𝗵𝗼𝘀 How does Bill Meury celebrate a $14 billion merger? With a new post at a Blackstone-founded biotech. Meury has been appointed CEO at Anthos Therapeutics, just over a month after closing Karuna Therapeutics’ sale to Bristol Myers Squibb. He previously held senior roles at Allergan and Actavis (now Allergan). Anthos, which spun out of Novartis in 2019, is developing a next-generation blood thinner designed to prevent strokes and clots, but with lower risk of bleeding than current therapies. Recent Phase 2 results suggest a 150 mg dose of the candidate, abelacimab, reduced the risk of bleeding by 67% compared to Bayer and Johnson & Johnson’s blockbuster Xarelto in patients with atrial fibrillation. https://lnkd.in/euqnUDSd

🌟 Exciting Announcement! New for 2024 🌟 Join us at the highly anticipated Prefilled Syringes East Coast 2024 for our enlightening Roundtable Discussion Sessions! Whether you're involved in device development, drug delivery, these sessions are crafted to enhance knowledge and spark collaborations. Roundtable Discussions Include: 🔹 Roundtable 1: Effective device lifecycle management strategies from early R&D to commercial launch Primary Perspective: Ning Yu, Executive Director, Astria Therapeutics, Inc. Commercial Perspective: Terry O’Hagan, General Manager, Haselmeier™ A medmix Brand 🔹 Roundtable 2: Successfully integrating combination product development with wider drug product development Primary Perspective: Michael Song, Director, Moderna Commercial Perspective: John Merhige, CEO, CREDENCE MEDSYSTEMS, INC. 🔹 Roundtable 3: Designing the next generation of combination products meeting needs of merging drug products via material choices and more Primary Perspective: Theresa Scheuble, Head of Design & Innovation, Johnson & Johnson Commercial Perspective: Charlie Dean, Head of Sustainable Medical Technology, Cambridge Consultants Don’t miss the chance to engage with industry leaders and peers in a dynamic setting, exploring groundbreaking strategies and the future of prefilled syringes and combination products. Secure one of the last remaining tickets here > https://ow.ly/n92750RiUrU

Pharma CDMO industry is changing fast! And leading companies who see the right trends can capitalize on this change by capturing higher market share, while getting better at operational efficiency & customer-centricity! Nice article below on some of the key trends! I liked the “CdMO” term coined as “Customer-driven Manufacturing Organization”!

We are excited to have Auxilius Pharma joined by Science and Operations Manager, Dawid Chabowski, Ph.D. on BioNeex. Auxilius Pharma, an emerging specialized #pharmaceutical company, aims to address unmet healthcare needs in Cardiology disorders and specializes in identifying and optimizing drugs with well-established clinical history and value-added potential. Auxilius Pharma showcases a Phase 2 oral drug candidate with a dual mechanism of action optimized for a once-daily dosing regimen indicated in the treatment of chronic stable angina pectoris. Explore partnership and in-licensing opportunities now. Learn more about the innovation: https://bioneex.com/ #pharma #biotechnology #healthcare #cardiology #phase2 #clinicaltrials #innovation

I am excited to speak about a topic that is so relevant in todays world as we continue to navigate this new norm of virtual interactions. While more doors may be open to us within a virtual space, the importance of ensuring meaningful engagement increases. I would love to hear how you may be handling this as well, please share your thoughts below.

🎉 Get ready to unlock the keys to success in the small biopharma sector with Jerry W., Associate Director at Ascentage Pharma, LIVE at the 20th Biopharma Clinical Trials Nexus Conference! 🌟 Join Jerry as he delves into the dynamic world of "Effectively Steering Your Clinical Trials for Success in the Small Biopharma Sector." 🚀🔬 Dive deep into actionable strategies, insider tips, and real-world case studies tailored specifically for small biopharma innovators. 💡 Don't miss this exclusive opportunity to learn from one of the industry's brightest minds and gain the competitive edge you need to drive your clinical trials to success. 🎤 #BiopharmaClinicalTrials #Innovation #SuccessSecrets #SanDiegoConference

New FDA requirements and the IRA will create complexity in the coming year for #pharmaceuticals. These seismic shifts make engineering document management for GMP documents more important than ever. Check out our Guide on Conquering Regulatory Compliance Chaos in Life Sciences https://lnkd.in/gb664cKU #pharmavoice #biomedicalengineering #pharmaceutical #gmp #documentmanagement https://lnkd.in/eM8RAs_W